Previous studies have shown that HDACi (e.g. givinostat and vorinostat, also identified in our screen) downregulate MYB gene expression in myeloproliferative neoplasms and myeloid leukemias (36, 39). This evidence concerns the gene MYB and myeloproliferative disorder.